Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12779/6537
DC FieldValueLanguage
dc.contributor.authorCasini, Nadiaen_us
dc.contributor.authorForte, Iris Mariaen_us
dc.contributor.authorMastrogiovanni, Gianmarcoen_us
dc.contributor.authorPentimalli, Francescaen_us
dc.contributor.authorAngelucci, Adrianoen_us
dc.contributor.authorFestuccia, Claudioen_us
dc.contributor.authorTomei, Valentinaen_us
dc.contributor.authorCeccherini, Elisaen_us
dc.contributor.authorDi Marzo, Domenicoen_us
dc.contributor.authorSchenone, Silviaen_us
dc.contributor.authorBotta, Maurizioen_us
dc.contributor.authorGiordano, Antonioen_us
dc.contributor.authorIndovina, Paolaen_us
dc.date.accessioned2021-03-30T16:04:02Z-
dc.date.available2021-03-30T16:04:02Z-
dc.date.issued2015-
dc.identifier.issn1949-2553en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12779/6537-
dc.description91071en_US
dc.description.abstractRecent data suggest that SRC family kinases (SFKs) could represent potential therapeutic targets for rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children. Here, we assessed the effect of a recently developed selective SFK inhibitor (a pyrazolo[3,4-d]pyrimidine derivative, called SI221) on RMS cell lines. SI221, which showed to be mainly effective against the SFK member YES, significantly reduced cell viability and induced apoptosis, without affecting non-tumor cells, such as primary human skin fibroblasts and differentiated C2C12 cells. Moreover, SI221 decreased in vitro cell migration and invasion and reduced tumor growth in a RMS xenograft model. SFK inhibition also induced muscle differentiation in RMS cells by affecting the NOTCH3 receptor-p38 mitogen-activated protein kinase (MAPK) axis, which regulates the balance between proliferation and differentiation. Overall, our findings suggest that SFK inhibition, besides reducing RMS cell growth and invasive potential, could also represent a differentiation therapeutic strategy for RMS.en_US
dc.language.isoenen_US
dc.relationNoneen_US
dc.relation.ispartofONCOTARGETen_US
dc.subjectNOTCH3; SRC family inhibition; YES; muscle differentiation; p38 MAPK; rhabdomyosarcoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Movement; Cell Proliferation; Cell Survival; Fluorescent Antibody Technique; Humans; Mice; Polymerase Chain Reaction; Pyrazoles; Pyrimidines; Rhabdomyosarcoma; Xenograft Model Antitumor Assays; p38 Mitogen-Activated Protein Kinases; src-Family Kinasesen_US
dc.titleSRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiationen_US
dc.typeArticleen_US
dc.identifier.doi10.18632/oncotarget.3043en_US
dc.identifier.pmid25762618en_US
dc.identifier.isiWOS:000359008200050en_US
dc.relation.volume6en_US
dc.relation.issue14en_US
dc.description.firstpage12421en_US
dc.description.lastpage12435en_US
dc.description.thirdmissionNot applicableen_US
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeArticle-
item.fulltextNo Fulltext-
crisitem.author.orcid0000-0003-0456-6995-
Appears in Collections:Publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.